

*To the Copenhagen Stock Exchange
and the Press*

Release no. 19/2007

Pharmexa: Presentation at ASCO on June 4, 2007

Summary: The presentation concerns Pharmexa's RAS peptide vaccines in patients with resectable pancreatic cancer

Professor Trond Buanes from Ullevål University Hospital in Norway will on Monday June 4, 2007 present a poster titled "*RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival*" at ASCO's (American Society of Clinical Oncology) annual cancer meeting.

The data concerns treatment of patients with resectable pancreatic cancer with two peptide vaccines aimed at a specific cancer mutation known as RAS. Rights to these vaccines belong to Pharmexa.

The 2007 ASCO conference will take place from June 1 to June 5 in Chicago, Illinois. It is widely regarded as the most important cancer conference in the world and attracted around 30,000 attendants last year.

Hørsholm, May 29, 2007

Jakob Schmidt
Chief Executive Officer

Additional information:

Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525

Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

Note to editors: *Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.*